Cargando…
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
INTRODUCTION: Various agents used in breast cancer chemotherapy provoke DNA double-strand breaks (DSBs). DSB repair competence determines the sensitivity of cells to these agents whereby aberrations in the repair machinery leads to apoptosis. Proteins required for this pathway can be detected as nuc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879561/ https://www.ncbi.nlm.nih.gov/pubmed/20205718 http://dx.doi.org/10.1186/bcr2486 |
_version_ | 1782181944983814144 |
---|---|
author | Asakawa, Hideki Koizumi, Hirotaka Koike, Ayaka Takahashi, Makiko Wu, Wenwen Iwase, Hirotaka Fukuda, Mamoru Ohta, Tomohiko |
author_facet | Asakawa, Hideki Koizumi, Hirotaka Koike, Ayaka Takahashi, Makiko Wu, Wenwen Iwase, Hirotaka Fukuda, Mamoru Ohta, Tomohiko |
author_sort | Asakawa, Hideki |
collection | PubMed |
description | INTRODUCTION: Various agents used in breast cancer chemotherapy provoke DNA double-strand breaks (DSBs). DSB repair competence determines the sensitivity of cells to these agents whereby aberrations in the repair machinery leads to apoptosis. Proteins required for this pathway can be detected as nuclear foci at sites of DNA damage when the pathway is intact. Here we investigate whether focus formation of repair proteins can predict chemosensitivity of breast cancer. METHODS: Core needle biopsy specimens were obtained from sixty cases of primary breast cancer before and 18-24 hours after the first cycle of neoadjuvant epirubicin plus cyclophosphamide (EC) treatment. Nuclear focus formation of DNA damage repair proteins was immunohistochemically analyzed and compared with tumor response to chemotherapy. RESULTS: EC treatment induced nuclear foci of γH2AX, conjugated ubiquitin, and Rad51 in a substantial amount of cases. In contrast, BRCA1 foci were observed before treatment in the majority of the cases and only decreased after EC in thirteen cases. The presence of BRCA1-, γH2AX-, or Rad51-foci before treatment or the presence of Rad51-foci after treatment was inversely correlated with tumor response to chemotherapy. DNA damage response (DDR) competence was further evaluated by considering all four repair indicators together. A high DDR score significantly correlated with low tumor response to EC and EC + docetaxel whereas other clinicopathological factors analyzed did not. CONCLUSIONS: High performing DDR focus formation resulted in tumor resistance to DNA damage-inducing chemotherapy. Our results suggested an importance of evaluation of DDR competence to predict breast cancer chemosensitivity, and merits further studying into its usefulness in exclusion of non-responder patients. |
format | Text |
id | pubmed-2879561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28795612010-06-02 Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins Asakawa, Hideki Koizumi, Hirotaka Koike, Ayaka Takahashi, Makiko Wu, Wenwen Iwase, Hirotaka Fukuda, Mamoru Ohta, Tomohiko Breast Cancer Res Research article INTRODUCTION: Various agents used in breast cancer chemotherapy provoke DNA double-strand breaks (DSBs). DSB repair competence determines the sensitivity of cells to these agents whereby aberrations in the repair machinery leads to apoptosis. Proteins required for this pathway can be detected as nuclear foci at sites of DNA damage when the pathway is intact. Here we investigate whether focus formation of repair proteins can predict chemosensitivity of breast cancer. METHODS: Core needle biopsy specimens were obtained from sixty cases of primary breast cancer before and 18-24 hours after the first cycle of neoadjuvant epirubicin plus cyclophosphamide (EC) treatment. Nuclear focus formation of DNA damage repair proteins was immunohistochemically analyzed and compared with tumor response to chemotherapy. RESULTS: EC treatment induced nuclear foci of γH2AX, conjugated ubiquitin, and Rad51 in a substantial amount of cases. In contrast, BRCA1 foci were observed before treatment in the majority of the cases and only decreased after EC in thirteen cases. The presence of BRCA1-, γH2AX-, or Rad51-foci before treatment or the presence of Rad51-foci after treatment was inversely correlated with tumor response to chemotherapy. DNA damage response (DDR) competence was further evaluated by considering all four repair indicators together. A high DDR score significantly correlated with low tumor response to EC and EC + docetaxel whereas other clinicopathological factors analyzed did not. CONCLUSIONS: High performing DDR focus formation resulted in tumor resistance to DNA damage-inducing chemotherapy. Our results suggested an importance of evaluation of DDR competence to predict breast cancer chemosensitivity, and merits further studying into its usefulness in exclusion of non-responder patients. BioMed Central 2010 2010-03-05 /pmc/articles/PMC2879561/ /pubmed/20205718 http://dx.doi.org/10.1186/bcr2486 Text en Copyright ©2010 Asakawa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research article Asakawa, Hideki Koizumi, Hirotaka Koike, Ayaka Takahashi, Makiko Wu, Wenwen Iwase, Hirotaka Fukuda, Mamoru Ohta, Tomohiko Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title_full | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title_fullStr | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title_full_unstemmed | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title_short | Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins |
title_sort | prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of dna damage repair proteins |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879561/ https://www.ncbi.nlm.nih.gov/pubmed/20205718 http://dx.doi.org/10.1186/bcr2486 |
work_keys_str_mv | AT asakawahideki predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT koizumihirotaka predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT koikeayaka predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT takahashimakiko predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT wuwenwen predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT iwasehirotaka predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT fukudamamoru predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins AT ohtatomohiko predictionofbreastcancersensitivitytoneoadjuvantchemotherapybasedonstatusofdnadamagerepairproteins |